查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1470458

生物模拟市场：按产品、交付模式、最终用户、应用划分 - 2024-2030 年全球预测

Biosimulation Market by Offering (Services, Software), Delivery Model (Ownership Models, Subscription Models), End-User, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年生物模拟市场规模为38.1亿美元，预计2024年将达44亿美元，2030年将达98.7亿美元，复合年增长率为14.55%。

生物模拟结合了数学、生物学和电脑程式设计来创建模拟来检验假设、预测结果并探索生物技术的新可能性。生物模拟透过模拟基因表现、新陈代谢和细胞生长等生物现象，帮助研究人员更好地了解生命的复杂性并开发医疗保健新产品。随着新药和药品开发的不断进步，以及政府专注于将数位化位技术整合到製药和生物製药领域，对生物模拟系统的需求不断增加。然而，开发模拟软体的高成本阻碍了市场的成长。由于电脑辅助设计（CAD）和虚拟实境（VR）技术的日益融合，以及人工智慧（AI）和机器学习（ML）在新模拟软体开发中的进步，生物模拟市场预计将扩大马苏。

主要市场统计
基准年[2023] 38.1亿美元
预测年份 [2024] 44亿美元
预测年份 [2030] 98.7亿美元
复合年增长率（%） 14.55%

生物模拟软体为模型建构、模拟、分析和视觉化提供平台，其使用正在不断增加。

合约服务由专业公司和研究组织提供，为其客户提供生物模拟专业知识，支援模型开发、模拟研究、资料分析和解释。内部服务是在组织或研究机构内执行的生物模拟服务。分子建模和模拟软体专注于对蛋白质、核酸和小分子等分子的行为进行模拟和建模。它用于研究分子之间的相互作用和结构变化，并预测结合亲和性等特性。 PBPK建模和模拟软体旨在模拟药物和化学物质的生物分布、吸收、代谢和排泄。 PK/PD、建模和模拟软体影响药物的药物动力学和动态特性，帮助预测药物浓度和暴露-反应关係，并优化给药方案。毒性预测软体专注于预测化合物的潜在毒性。计算模型用于评估接触特定化学物质和药物的安全性和潜在风险。临床试验设计软体支援临床试验设计和最佳化，模拟各种临床试验场景，评估统计功效，优化样本大小，以提高临床试验的效率和有效性。

交付模型：生物模拟倾向于支援为使用者提供完全控制的所有权模型。

生物模拟的所有权模型允许使用者购买软体和服务，并完全控制软体及其使用方式。在生物模拟所有权模型中，使用者购买软体的永久许可证，并被授予无限期使用该软体的权利。在订阅模式中，使用者支付经常性费用才能存取和使用软体和服务。在此模型中，使用者通常不拥有该软体，但可以持续存取最新版本和更新。

最终用户：製药和生物技术公司越来越多地采用生物模拟

委外研发机构(CRO) 经常利用生物模拟来支援客户的药物发现和研发流程，包括使用生物模拟技术进行分子建模、PK/PD 建模、毒性预测等。製药和生物技术公司在其药物开发平臺中广泛采用生物模拟。包括美国食品药物管理局(FDA) 和欧洲药品管理局 (EMA) 在内的监管机构在核准药品上市之前评估药品的安全性和有效性方面发挥着重要作用。监管机构使用生物模拟来评估药物的风险效益状况、优化研究设计并在医药品认证过程中做出明智的决定。学术机构和政府机构等研究组织使用生物模拟来提高科学知识并进行高级研究。研究人员使用生物模拟工具和技术来建模和模拟复杂的生物系统，探索假设，并深入了解基本的生物过程。

将生物模拟的应用扩展到应用药物开发

生物模拟提供有关药物的药物动力学 (PK) 和动态(PD) 特性的见解和预测，以优化给药方案、预测目标组织中的药物浓度以及候选药物的潜在功效和安全性，它在药物开发中发挥重要作用。 PBPK 和 PK/PD 建模等生物模拟技术可支援药物开发中的明智决策。生物模拟支持临床试验的设计和最佳化，并能够预测和评估药物和化合物的吸收、分布、代谢、排泄和毒性特性。生物模拟可以在药物开发过程的早期识别潜在的 ADME/Tox 问题，从而减少广泛的动物测试的需要并提供对潜在风险的洞察。 PK/PD建模和模拟可以预测药物暴露和反应性之间的关係。生物模拟透过采用分子建模和模拟技术来支持先导化合物的识别和最佳化。帮助筛检和评估潜在的候选药物，预测与目标分子的结合亲和性，并优化化学结构以提高效力和选择性。生物模拟技术可以帮助识别和检验潜在的药物标靶。生物模拟透过建模和模拟药物分子与目标蛋白之间的相互作用，有助于评估靶向特定蛋白的可行性和潜在有效性。

区域洞察

美洲地区是生物模拟市场高度发展的地区。这是由于美国现有主要参与者的存在以及他们对推进模拟软体的持续努力。 FDA（美国食品药物管理局）、EMA（欧洲药品管理局）和加拿大卫生署等监管机构的成立，确保药物开发和临床试验的安全性和效率，为亚太地区的市场成长做出贡献。 。就欧洲、中东和非洲地区而言，英国、德国和法国对药物开发和临床试验的投资增加正在推动模拟软体和服务的采用。亚太地区慢性病的增加预计将促使各国政府和监管机构加强对药物开发的资助力度，为生物模拟市场的开拓提供平台。针对药物研发 (R&D) 活动的各种倡议的存在，例如澳洲药物发现计划和医学研究商业化计划，正在扩大生物模拟在亚太地区的使用。

FPNV定位矩阵

FPNV定位矩阵对于评估生物模拟市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对生物模拟市场中供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.生物模拟市场的市场规模与预测是多少？

2.在生物模拟市场的预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.生物模拟市场的技术趋势和法规结构是什么？

4.生物模拟市场主要厂商的市场占有率为何？

5. 进入生物模拟市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 专注于个人化医疗研究
      • 监管部门核准使用生物模拟加速安全药物开发
    • 抑制因素
      • 与生物模拟安装和技术开发相关的价格上涨
    • 机会
      • 模拟解决方案不断进步，以增强新的生物疗法
      • 加大药物研发及药物检测投入
    • 任务
      • 复杂性和缺乏产生准确结果的意识
  • 市场区隔分析
    • 它提供什么：增加生物模拟中软体的使用，提供模型建构、模拟、分析和视觉化平台
    • 分配模型：生物模拟中越来越倾向于所有权模型，以便为使用者提供完全控制
    • 最终用户：扩大生物模拟在製药和生物技术公司的采用
    • 应用：扩大生物模拟在药物开发的应用
  • 市场趋势分析
    • 对药物开发和合作进行大量投资，以扩大生物模拟在美洲的使用
    • 政府推动亚太地区药物研究创新技术采用的倡议
    • 临床试验和药物开发活动的增加扩大了欧洲、中东和非洲地区生物模拟的范围
  • 俄罗斯和乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章生物模拟市场：透过提供

  • 服务
  • 软体

第七章依分布模型分類的生物模拟市场

  • 所有权模式
  • 订阅模式

第 8 章生物模拟市场：依最终用户分类

  • 合约调查机构
  • 製药和生物技术公司
  • 监管机构
  • 调查机构

第九章生物模拟市场：依应用分类

  • 药物开发
  • 药物发现

第10章美洲生物模拟市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太生物模拟市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲生物模拟市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Certara 和 DNDi 联手加快资料提交速度并加快延迟治疗患者的药物核准
    • Certara 发布用于药物开发的 Phoenix 生物模拟模拟软体8.4 版
    • Certara 利用人工智慧增强药物发现的 CODEX 平台
    • Simulations Plus 推出新的整合式肺部软体和服务包，旨在简化药物开发并改善患者治疗结果
    • Simulations Plus 取得美国FDA 续签 DILIsym 软体许可证
    • Simulations Plus 建立合作伙伴关係，透过应用 AI/ML 技术设计新化合物
    • Simulations Plus 发表重新设计的 NAFLDsym QSP 软体工具
    • Cellworks 进军精准医疗业务，加速癌症药物开发并重振搁置的製药资产
    • Certara 收购 Vyasa，一家提供预测以加速科学创新的人工智慧公司
    • Applied BioMath LLC 宣布与 SpringWorks Therapeutics 合作进行多发性骨髓瘤的系统药理学建模
    • Applied BioMath LLC 宣布继续与摄氏度疗法在发炎性肠道疾病的系统药理学建模方面合作
    • GNS 和施维雅宣布人工智慧合作，推动多发性骨髓瘤治疗的药物发现和临床开发
    • Cadence 透过收购计算分子设计领域的先驱领导者 OpenEye Scientific 进军分子模拟领域
    • 解析度 Medical 收购先健科技集团
    • Colorcon Ventures 投资人工智慧驱动的生物模拟公司 VeriSIM Life

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-2D64BA93AB17

[197 Pages Report] The Biosimulation Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.40 billion in 2024, at a CAGR 14.55% to reach USD 9.87 billion by 2030.

Biosimulation combines mathematics, biology, and computer programming to create simulations to test hypotheses, predict outcomes, and explore new possibilities in biotechnology. By simulating biological phenomena such as gene expression, metabolism, and cell growth, biosimulation helps researchers better understand the complexities of life and develop new products for healthcare. The increasing development of new drugs and medicines and the growing government focus on integrating digitalized technologies in pharmaceutical and biopharmaceutical sectors are elevating the need for biosimulation systems. However, the high cost associated with developing biosimulation software hampers market growth. The growing integration of computer-aided design (CAD) and virtual reality (VR) technologies, as well as advancements in artificial intelligence (AI) and machine learning (ML) for the development of new biosimulation software, is expected to expand the scope of the biosimulation market.

KEY MARKET STATISTICS
Base Year [2023] USD 3.81 billion
Estimated Year [2024] USD 4.40 billion
Forecast Year [2030] USD 9.87 billion
CAGR (%) 14.55%

Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization

Contract services are provided by specialized companies and research organizations that offer biosimulation expertise to clients, which assist with model development, simulation studies, data analysis, and interpretation. In-house services are biosimulation services conducted within an organization and research institution. Molecular modeling & simulation software focuses on simulating and modeling the behavior of molecules, such as proteins, nucleic acids, and small molecules. It is used to study molecular interactions and conformational changes and predict properties such as binding affinity. PBPK modeling & simulation software is designed to simulate the distribution, absorption, metabolism, and excretion of drugs and chemicals in the body. PK/PD, modeling & simulation software, affects drugs' pharmacokinetic and pharmacodynamic properties, helps predict drug concentrations and exposure-response relationships, and optimizes dosing regimens. Toxicity prediction software focuses on predicting the potential toxicity of chemical compounds. It uses computational models to assess the safety and potential risks of exposure to specific chemicals or drugs. Trial design software helps in the design and optimization of clinical trials and also simulates different trial scenarios, evaluates statistical power, and optimizes sample sizes to improve the efficiency and validity of clinical studies.

Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users

In the biosimulation ownership model, users purchase the software and service outright, giving them full control over the software and its usage. In the biosimulation ownership model, users purchase a perpetual license for the software, granting them the right to use it indefinitely. Subscription models involve users paying a recurring fee to access and use the software or services. With this model, users usually do not own the software but have ongoing access to the latest versions and updates.

End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies

Contract research organizations (CROs) often utilize biosimulation to support their clients' drug discovery and development processes and offer services such as molecular modeling, PK/PD modeling, toxicity prediction, and trial design using biosimulation techniques. Pharmaceutical & biotechnology companies extensively employ biosimulation throughout the drug development pipeline. Regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), play a crucial role in evaluating drug safety and effectiveness before being approved for market release. Regulatory authorities use biosimulation to assess the risk-benefit profile of drugs, optimize study designs, and make informed decisions during the drug approval process. Research institutes, including academic institutions and government organizations, employ biosimulation to advance scientific knowledge and conduct advanced research. Researchers utilize biosimulation tools and techniques to model and simulate complex biological systems, explore hypotheses, and gain insights into fundamental biological processes.

Application: Increasing application of biosimulation for drug development

Biosimulation plays a vital role in drug development by providing insights and predictions related to drug pharmacokinetic (PK) and pharmacodynamic (PD) properties, assisting in optimizing dosing regimens, predicting drug concentrations in target tissues, and assessing drug candidates' potential efficacy and safety. Biosimulation techniques, such as PBPK and PK/PD modeling, aid in making informed decisions during drug development. Biosimulation supports the design and optimization of clinical trials and enables the prediction and evaluation of drugs and chemical compounds' absorption, distribution, metabolism, excretion, and toxicity properties. Biosimulation helps identify potential ADME/Tox issues early in the drug development process, reducing the need for extensive animal testing and providing insights into potential risks. PK/PD modeling and simulation assist in predicting the relationship between drug exposure and response. Biosimulation supports lead identification & optimization by employing molecular modeling and simulation techniques. It aids in screening and evaluating potential drug candidates, predicting their binding affinity to target molecules, and optimizing their chemical structures for improved potency and selectivity. Biosimulation techniques aid in the identification and validation of potential drug targets. By modeling and simulating the interactions between drug molecules and target proteins, biosimulation helps evaluate the feasibility and potential effectiveness of targeting specific proteins.

Regional Insights

The Americas region showcases a highly developing landscape for the biosimulation market owing to the presence of major established players in the United States and their ongoing efforts to advance biosimulation software. Well-established regulatory authorities such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada to ensure the safety and efficiency of drug development and clinical trials are benefiting the market growth across the Americas, Europe, and Asia-Pacific. Considering the EMEA region, the increasing investment in drug development and clinical trials across UK, Germany, and France is expanding the adoption of biosimulation software & services. The increasing number of chronic diseases across Asia-Pacific encourages government and regulatory authorities to expand their funding activities for drug development which is expected to create a platform for developing the biosimulation market. The presence of various initiatives such as Australia's Drug Discovery Initiative and Medical Research Commercialisation Initiative that aims at pharmaceutical research and development (R&D) activities is expanding the usage of biosimulation in Asia-pacific.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Biosimulation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biosimulation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Applied BioMath, LLC, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Compugen Ltd., Crystal Pharmatech Co., Ltd., Dassault Systemes SE, Genedata AG, Immunetrics Inc, In Silico Biosciences, Inc., INOSIM Software GmbH, Instem PLC, Laboratory Corporation of America Holdings, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Rosa & Co LLC, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life., VIRTUALMAN, and Yokogawa Electric Corporation.

Market Segmentation & Coverage

This research report categorizes the Biosimulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Offering
    • Services
      • Contract Services
      • In-House Services
    • Software
      • Molecular Modeling & Simulation Software
      • PBPK Modeling & Simulation Software
      • PK/PD Modeling & Simulation Software
      • Toxicity Prediction Software
      • Trial Design Software
  • Delivery Model
    • Ownership Models
    • Subscription Models
  • End-User
    • Contract Research Organizations
    • Pharmaceutical & Biotechnology Companies
    • Regulatory Authorities
    • Research Institutes
  • Application
    • Drug Development
      • Clinical Trials
      • Preclinical Testing
        • ADME/Tox
        • PK/PD
    • Drug Discovery
      • Lead Identification & Optimization
      • Target Identification & Validation
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Biosimulation Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biosimulation Market?

3. What are the technology trends and regulatory frameworks in the Biosimulation Market?

4. What is the market share of the leading vendors in the Biosimulation Market?

5. Which modes and strategic moves are suitable for entering the Biosimulation Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing emphasis on research of personalized medicine
      • 5.1.1.2. Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
    • 5.1.2. Restraints
      • 5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in simulation solutions to enhance the novel biologic therapies
      • 5.1.3.2. Rising investments for drug developments and drug testings
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness coupled with complexities for creating accurate outcomes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
    • 5.2.2. Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users
    • 5.2.3. End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
    • 5.2.4. Application: Increasing application of biosimulation for drug development
  • 5.3. Market Trend Analysis
    • 5.3.1. Significant investments in drug development and collaborative activities to expand the usage of biosimulation in the Americas
    • 5.3.2. Government initiatives to encourage the adoption of innovative technologies in pharmaceutical research in the APAC
    • 5.3.3. Increasing clinical trials and drug development activities expanding the scope of biosimulation in the EMEA region
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis

6. Biosimulation Market, by Offering

  • 6.1. Introduction
  • 6.2. Services
  • 6.3. Software

7. Biosimulation Market, by Delivery Model

  • 7.1. Introduction
  • 7.2. Ownership Models
  • 7.3. Subscription Models

8. Biosimulation Market, by End-User

  • 8.1. Introduction
  • 8.2. Contract Research Organizations
  • 8.3. Pharmaceutical & Biotechnology Companies
  • 8.4. Regulatory Authorities
  • 8.5. Research Institutes

9. Biosimulation Market, by Application

  • 9.1. Introduction
  • 9.2. Drug Development
  • 9.3. Drug Discovery

10. Americas Biosimulation Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biosimulation Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biosimulation Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Certara and DNDi Partnering to Fast-track Data Submissions and Accelerate Drug Approvals for Neglected Patients
    • 13.3.2. Certara Launches Version 8.4 of Phoenix Biosimulation Software for Drug Development
    • 13.3.3. Certara Amplifies CODEX Platform Capabilities with AI for Drug Discovery
    • 13.3.4. Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
    • 13.3.5. Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
    • 13.3.6. Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
    • 13.3.7. Simulations Plus Releases Redesigned NAFLDsym QSP Software Tool
    • 13.3.8. Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets
    • 13.3.9. Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
    • 13.3.10. Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma
    • 13.3.11. Applied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease
    • 13.3.12. GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
    • 13.3.13. Cadence Expands into Molecular Simulation with Acquisition of OpenEye Scientific, a Pioneering Leader in Computational Molecular Design
    • 13.3.14. Resolution Medical Acquires LifeTec Group
    • 13.3.15. Colorcon Ventures Invests in AI-Driven Bio-simulation Company VeriSIM Life

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BIOSIMULATION MARKET RESEARCH PROCESS
  • FIGURE 2. BIOSIMULATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BIOSIMULATION MARKET DYNAMICS
  • FIGURE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. BIOSIMULATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. BIOSIMULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOSIMULATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BIOSIMULATION MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIOSIMULATION MARKET SIZE, BY ADME/TOX, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL BIOSIMULATION MARKET SIZE, BY ADME/TOX, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 81. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 84. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 85. AMERICAS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 86. AMERICAS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 87. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 88. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 89. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 90. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 93. ARGENTINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 94. ARGENTINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 95. ARGENTINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 96. ARGENTINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 97. ARGENTINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 98. ARGENTINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 99. ARGENTINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 100. ARGENTINA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 101. ARGENTINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. ARGENTINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 104. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 105. ARGENTINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 106. ARGENTINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 107. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 108. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 109. BRAZIL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 110. BRAZIL BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 111. BRAZIL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 112. BRAZIL BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 113. BRAZIL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 114. BRAZIL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 115. BRAZIL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 116. BRAZIL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 117. BRAZIL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 118. BRAZIL BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 119. BRAZIL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. BRAZIL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 122. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 123. BRAZIL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 124. BRAZIL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 125. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 126. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 127. CANADA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 128. CANADA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 129. CANADA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 130. CANADA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 131. CANADA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 132. CANADA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 133. CANADA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 134. CANADA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 135. CANADA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 136. CANADA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 137. CANADA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. CANADA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 140. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 141. CANADA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 142. CANADA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 143. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 144. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 145. MEXICO BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 146. MEXICO BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 147. MEXICO BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 148. MEXICO BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 149. MEXICO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 150. MEXICO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 151. MEXICO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 152. MEXICO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 153. MEXICO BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 154. MEXICO BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 155. MEXICO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. MEXICO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 158. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 159. MEXICO BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 160. MEXICO BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 161. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 162. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 163. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 164. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 165. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 166. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 167. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 168. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 169. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 170. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 171. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 176. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 177. UNITED STATES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 178. UNITED STATES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 179. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 180. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 181. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 182. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 203. AUSTRALIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 204. AUSTRALIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 205. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 206. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 207. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 208. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 209. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 210. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 211. AUSTRALIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. AUSTRALIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. AUSTRALIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. AUSTRALIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 216. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 217. AUSTRALIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 218. AUSTRALIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 219. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 220. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 221. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 222. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 223. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 224. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 225. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 226. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 227. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 228. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 229. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 230. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 231. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 234. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 235. CHINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 236. CHINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 237. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 238. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 239. INDIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 240. INDIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 241. INDIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 242. INDIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 243. INDIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 244. INDIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 245. INDIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 246. INDIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 247. INDIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 248. INDIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 249. INDIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. INDIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 252. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 253. INDIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 254. INDIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 255. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 256. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 257. INDONESIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 258. INDONESIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 259. INDONESIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 260. INDONESIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 261. INDONESIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 262. INDONESIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 263. INDONESIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 264. INDONESIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 265. INDONESIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 266. INDONESIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 267. INDONESIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. INDONESIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 270. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 271. INDONESIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 272. INDONESIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 273. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 274. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 275. JAPAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 276. JAPAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 277. JAPAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 278. JAPAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 279. JAPAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 280. JAPAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 281. JAPAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 282. JAPAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 283. JAPAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. JAPAN BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. JAPAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. JAPAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 288. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 289. JAPAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 290. JAPAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 291. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 292. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 293. MALAYSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 294. MALAYSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 295. MALAYSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 296. MALAYSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 297. MALAYSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 298. MALAYSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 299. MALAYSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 300. MALAYSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 301. MALAYSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 302. MALAYSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 303. MALAYSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 304. MALAYSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 305. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 306. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 307. MALAYSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 308. MALAYSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 309. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 310. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 311. PHILIPPINES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 312. PHILIPPINES BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 313. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 314. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 315. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 316. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 317. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 318. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 319. PHILIPPINES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 320. PHILIPPINES BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 321. PHILIPPINES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 322. PHILIPPINES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 323. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 324. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 325. PHILIPPINES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 326. PHILIPPINES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 327. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 328. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 329. SINGAPORE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 330. SINGAPORE BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 331. SINGAPORE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 332. SINGAPORE BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 333. SINGAPORE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 334. SINGAPORE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 335. SINGAPORE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 336. SINGAPORE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 337. SINGAPORE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 338. SINGAPORE BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 339. SINGAPORE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 340. SINGAPORE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 341. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 342. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 343. SINGAPORE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 344. SINGAPORE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 345. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 346. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 347. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 348. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 349. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 350. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 351. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 352. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 353. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 354. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 355. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 356. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 357. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 358. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 359. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 360. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 361. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 362. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 363. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 364. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 365. TAIWAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 366. TAIWAN BIOSIMULATION MARKET SIZE, BY OFFERING,